Literature DB >> 17593277

International workshop on immune tolerance induction: consensus recommendations.

D M DiMichele1, W K Hoots, S W Pipe, G E Rivard, E Santagostino.   

Abstract

Although immune tolerance induction (ITI) has been used for 30 years to eliminate inhibitors and restore normal factor pharmacokinetics in patients with hemophilia, there is a paucity of scientific evidence to guide therapeutic decision-making. In an effort to provide direction for physicians and hemophilia treatment center staff members, an international panel of hemophilia opinion leaders met to develop consensus recommendations for ITI in patients with severe and mild hemophilia A and hemophilia B. These recommendations draw on the available published literature and the collective clinical experience of the group and are rated based on the level of supporting evidence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593277     DOI: 10.1111/j.1365-2516.2007.01497.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  56 in total

1.  Report of the Fifth meeting of the International Network for Pediatric Hemophilia: a focus on prophylaxis and immune tolerance induction.

Authors:  Rolf Ljung; Johannes Oldenburg; Günter Auerswald; Marijke van den Berg; Midori Shima; Donna DiMichele
Journal:  Int J Hematol       Date:  2011-09-28       Impact factor: 2.490

2.  Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 3.  Barriers to primary prophylaxis in haemophilic children: the issue of the venous access.

Authors:  Elena Santagostino; Maria Elisa Mancuso
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

Review 4.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 5.  Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.

Authors:  Antonio Coppola; Annarita Tagliaferri; Gabriele Calizzani; Fabio Candura; Massimo Franchini; Carlo Ruosi; Giuliano Grazzini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 6.  Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

7.  Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.

Authors:  Gianna Franca Rivolta; Caterina Di Perna; Massimo Franchini; Federica Riccardi; Luigi Ippolito; Maria Lombardi; Annarita Tagliaferri
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

8.  A role for von Willebrand factor in immune tolerance induction in patients with haemophilia A and inhibitors?

Authors:  Giovanni Di Minno; Antonio Coppola
Journal:  Blood Transfus       Date:  2011-05       Impact factor: 3.443

9.  Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.

Authors:  Angiola Rocino; Antonio Coppola; Massimo Franchini; Giancarlo Castaman; Cristina Santoro; Ezio Zanon; Elena Santagostino; Massimo Morfini
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 10.  Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Authors:  Johannes Oldenburg; Sébastien Lacroix-Desmazes; David Lillicrap
Journal:  Haematologica       Date:  2015-02       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.